EichorEICHOR
Condition: Moderate To Severe Crohn S Disease Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Moderate To Severe Crohn S Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Phase 2/Phase 3 · 368 location(s) · Janssen Research & Development, LLC · NCT07196722A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Phase 3 · 41 location(s) · Takeda · NCT05837897A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Phase 3 · 96 location(s) · Takeda · NCT04779320A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Di
Phase 3 · 499 location(s) · Merck Sharp & Dohme LLC · NCT06430801A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderate
Phase 3 · 196 location(s) · Hoffmann-La Roche · NCT06819891Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Phase 2 · 255 location(s) · AbbVie · NCT06548542A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Phase 2 · 71 location(s) · Eli Lilly and Company · NCT07483073A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · 85 location(s) · Janssen Research & Development, LLC · NCT05923073Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Col
Phase 1 · 30 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06754891Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Phase 2 · 149 location(s) · Abivax S.A. · NCT06456593A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Th
Phase 3 · 85 location(s) · AbbVie · NCT05995353A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
Phase 2 · 66 location(s) · Sanofi · NCT06958536A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Phase 2 · 139 location(s) · Sanofi · NCT06637631An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With
Phase N/A · 104 location(s) · AbbVie · NCT06023030A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Phase 2 · 71 location(s) · Eli Lilly and Company · NCT07483099Treatment of Moderate to Severe Refractory Crohn's Disease
Phase 1/Phase 2 · 13 location(s) · Tr1X, Inc. · NCT06721962InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
Phase 3 · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT06059989IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
Phase N/A · 1 location(s) · The Third Xiangya Hospital of Central South University · NCT07034664A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to
Phase 2 · 190 location(s) · Takeda · NCT06233461A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · 55 location(s) · Janssen Research & Development, LLC · NCT07577843A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Phase 2 · 16 location(s) · Takeda · NCT06764615A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Phase 3 · 54 location(s) · Takeda · NCT06100289Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severel
Phase 3 · 85 location(s) · AbbVie · NCT06332534A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Phase N/A · 1 location(s) · Takeda · NCT05428345Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
Phase N/A · 1 location(s) · Second Affiliated Hospital, Zhejiang University, School of M · NCT07385131A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in
Phase 3 · 7 location(s) · Hoffmann-La Roche · NCT07298421VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Phase 4 · 69 location(s) · Alimentiv Inc. · NCT06257706A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Phase 2 · 225 location(s) · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli · NCT06226883Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Ob
Phase 3 · 186 location(s) · Eli Lilly and Company · NCT06937099A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti
Phase 3 · 35 location(s) · Sanofi · NCT07184944
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.